Oxford Cancer Biomarkers launches ToxNav to improve morbidity and mortality rates in patients undergoing CRC chemotherapy

Jul 3, 2018

Oxford Cancer Biomarkers Limited  has announced the launch of ToxNav – a genomic test to identify cancer patients at high risk of severe and potentially fatal side-effects when treated with 5FU/Capecitabine chemotherapy. ToxNav helps clinicians to select safer chemotherapy regimens, thereby reducing both the likelihood of life-threatening toxicity and unnecessary treatment costs. Initially available for colorectal cancer, the company plans to develop ToxNav for other cancers for which 5FU/Capecitabine is the first-line chemotherapy. Colorectal cancer (CRC), is the fourth most common cancer in the UK and a significant number of CRC patients are genetically predisposed to severe side-effects from 5FU/Capecitabine ...

Read More

Needle-free Injection – Eradicating Diseases to Improve Global Health

Jan 4, 2018

Needle-free injection technology has evolved significantly over the last 50 years and is now accepted in many routine immunisation settings as a safe and effective vaccine delivery method. Disposable syringe jet injectors are now being used for the delivery of vaccines to eradicate polio, MMR, and influenza, and are showing promising results in vaccine clinical trials for the Zika virus and HPV. In her paper, Dr Erin Spiegel of PharmaJet shows that these devices are fast, safe, and easy to use, with most providers trained in less than 20 minutes. ...

Read More